Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.

@article{Oberg2012NeuroendocrineTO,
  title={Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.},
  author={Kjell E Oberg},
  journal={Current opinion in oncology},
  year={2012},
  volume={24 4},
  pages={433-40}
}
PURPOSE OF REVIEW Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) constitute a diverse group of neoplasms arising from the diffuse neuroendocrine cell system. During the last 2 years a new classification system, the WHO 2010, has come into clinical practice together with Tumor Nodes Metastases (TNM) staging and grading systems, developed by the European Neuroendocrine Tumor Society/American Joint Cancer Committee. At the same time new targeted agents have been developed for treatment of… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Gastroenteropancreatic neuroendocrine tumors ( GEP - NETs ) constitute a diverse group of neoplasms arising from the diffuse neuroendocrine cell system .
Gastroenteropancreatic neuroendocrine tumors ( GEP - NETs ) constitute a diverse group of neoplasms arising from the diffuse neuroendocrine cell system .
Gastroenteropancreatic neuroendocrine tumors ( GEP - NETs ) constitute a diverse group of neoplasms arising from the diffuse neuroendocrine cell system .
Gastroenteropancreatic neuroendocrine tumors ( GEP - NETs ) constitute a diverse group of neoplasms arising from the diffuse neuroendocrine cell system .
However , there are two phase III trials that have completely changed the treatment landscape for pancreatic neuroendocrine tumors , e.g. , sunitinib and everolimus demonstrating an increased progression free survival of 11 vs. 5 months for the placebo group .
Sunitinib and everolimus have recently been registered for treatment of pancreatic neuroendocrine tumors worldwide .
Sunitinib and everolimus have recently been registered for treatment of pancreatic neuroendocrine tumors worldwide .
However , there are two phase III trials that have completely changed the treatment landscape for pancreatic neuroendocrine tumors , e.g. , sunitinib and everolimus demonstrating an increased progression free survival of 11 vs. 5 months for the placebo group .
All Topics